time) after the fourth dose. This cleared within 24 hours after stopping EACA. The patient remained unconscious for about three months before she died.
Potentially dangerous effect of disopyramide on atrioventricular conduction in a patient on digitalis
The antiarrhythmic drug disopyramide prolongs the refractory period of atrial myocardium.1 It is therefore sometimes useful in treating ectopic atrial tachycardia. Disopyramide also has atropine-like properties2 which may lead to enhanced atrioventricular (AV) nodal conduction. The combination of slowing the atrial rate with "improved" AV nodal function may lead to 1:1 conduction of the tachycardia when previously it had been 2:1. This causes a potentially dangerous increase in ventricular rate. A similar increase may occur when disopyramide is given to patients in atrial fibrillation.3 For this reason patients should be digitalised before attempted conversion of atrial tachycardia with disopyramide. This report concems the failure of digitalis to protect a patient from this unwanted effect.
Case report
The patient, a 68-year-old woman, had a long history of rheumatic mitral stenosis. She had been well having no treatment other than warfarin until two months before admission, when she developed a fast heart rate and dyspnoea on minimal exertion. An electrocardiogram (ECG) showed atrial tachycardia with 2:1 conduction. Digoxin and propranolol failed to control the rhythm so she was admitted for a trial of disopyramide. On admission she was taking digoxin 0-25 mg and frusemide 40 mg once a day, potassium supplements, and warfarin. On examination she was euthyroid: pulse rate 125/min, regular; jugular venous pressure raised 3 cm; blood pressure 140/80 mm Hg. Both ventricular impulses were slightly increased and the murmurs of moderate mitral stenosis and incompetence were present. There were no signs of pulmonary oedema. Blood urea concentrations, electrolytes, and thyroid function tests were normal; haemoglobin concentration was 14-7 g/dl, and serum digoxin 1-4 mg/l. Chest radiographs showed mitral cardiac contour with clear lung fields, and an ECG showed atrial tachycardia with 2:1 conduction (figure (a)).
Disopyramide was given intravenously in a total dose of 1-5 mg/kg over five minutes with continuous ECG monitoring. Thirty seconds after the injection she developed 1:1 conduction ( figure(b) ). The atrial rate had slowed from 250 to 185. She became breathless and hypotensive. Three minutes later she reverted to 2:1 conduction with an atrial rate of 194 ( figure (c) ). 
Comment
The feature of interest in this case is that digitalis failed to protect the patient from the atropinic effect of disopyramide. Without an intracardiac study the relative contributions of enhanced AV conduction and slowing of the atrial rate cannot be disentangled nor can the effect of the digitalis on the AV node be assessed. Although the serum digoxin concentration may not be clearly related to its effect on AV nodal conduction, it is the only means available to most physicians to ensure adequate digitalisation. Caution should therefore be exercised when giving disopyramide to patients with atrial tachycardia even when they are taking digitalis. The same caution probably applies equally to treatment with quinidine, whose affect on electrophysiological pathways is very similar to that of disopyramide. This potential hazard should not detract from the usefulness of disopyramide in a condition which may be difficult to treat. 
